Perrigo Reaches $1.5bn Deal With Altaris For Rx Business
Company Announces Divestment After Holding Out For The Right Valuation
Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.
You may also be interested in...
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.
Padagis, the former Perrigo Rx business that was acquired by Altaris in July, has seen litigation initiated by Eucrisa originator Anacor over its Paragraph IV ANDA filing for crisaborole 2% ointment.